Cancer Policy & regulation Clinician / health professional

Roche breast cancer pill approved by FDA

By Published On: November 18, 2026
Roche breast cancer pill approved by FDA

The FDA has approved a new treatment option for advanced breast cancer after Roche’s Wilserdly combination significantly extended the time patients lived without their disease progressing.

The approval covers patients whose tumours carry an ESR1 mutation, a genetic alteration associated with resistance to some hormone treatments.

Wilserdly, also known as giredestrant, is an oral selective oestrogen receptor degrader (SERD). These medicines target the receptors that allow oestrogen to stimulate cancer growth.

The US Food and Drug Administration (FDA) granted approval on 16 November, approximately one month ahead of schedule.

The decision follows results from the phase 3 evERA trial, which tested Wilserdly alongside everolimus in patients previously treated with CDK4/6 inhibitors, a standard first-line treatment for certain types of advanced breast cancer.

Among patients with ESR1-mutated disease, the combination reduced the risk of cancer progression or death by 62 per cent compared with standard endocrine therapy plus everolimus.

Median progression-free survival reached 10 months with Wilserdly, compared with 5.5 months in the control group. This measures how long patients remain alive without their cancer worsening.

Roche said Wilserdly plus everolimus was the first oral SERD combination to show a statistically significant improvement over standard endocrine therapy in a phase 3 trial involving patients previously treated with CDK4/6 inhibitors.

The approval provides another treatment option for patients with ESR1-mutated advanced breast cancer who have already received treatment.

ESR1 mutations often develop after exposure to aromatase inhibitors, medicines that reduce oestrogen production. They are a recognised mechanism of treatment resistance in HR-positive, HER2-negative metastatic breast cancer.

Other FDA-approved oral SERDs include Menarini’s Orserdu, Eli Lilly’s Inluriyo and AstraZeneca’s Etcamah.

Orserdu and Inluriyo previously received approval for patients with ESR1-mutated tumours requiring further treatment.

In September, the FDA expanded Inluriyo’s approval to include its use with Eli Lilly’s CDK4/6 inhibitor Verzenio.

The decision followed the phase 3 Ember-3 trial, in which the combination improved progression-free survival by 47 per cent compared with Inluriyo alone.

Median progression-free survival reached 11.1 months with the combination, against 5.5 months for Inluriyo alone.

AstraZeneca’s Etcamah has been approved for a different approach, involving patients who develop an ESR1 mutation during initial treatment with an aromatase inhibitor and a CDK4/6 inhibitor.

That approval followed the phase 3 Serena-6 trial and was controversial because the FDA acted against a negative advisory committee recommendation.

The trial also left unanswered whether switching treatment before disease progression was at least as effective as waiting until the cancer worsens.

Both Etcamah and Wilserdly have previously failed to meet their objectives in first-line breast cancer trials, where ESR1 mutations are uncommon.

Despite its first-line setback, Roche is pursuing a role for Wilserdly in early-stage breast cancer.

Its phase 3 lidERA trial showed a statistically significant improvement in invasive disease-free survival compared with standard endocrine therapy. This measures how long patients remain free from invasive cancer returning or other qualifying disease events.

The FDA is expected to decide on Wilserdly’s proposed use as adjuvant treatment for early-stage breast cancer by 30 November 2026.

Adjuvant treatment is given after initial cancer treatment to reduce the risk of recurrence.

Roche sees this as a substantial commercial opportunity because more patients receive treatment in the early-stage setting and treatment generally lasts longer than in metastatic disease.

During an investor call in April, Teresa Graham, chief executive of Roche Pharmaceuticals, said early-stage treatment represented a much larger opportunity than first-line metastatic breast cancer.

The company has projected peak annual sales for Wilserdly exceeding 3bn Swiss francs.

Its potential use in early-stage disease remains under regulatory review.

MHRA programme to tackle evidence gaps on women’s health
Menopause Rocks launches midlife women’s health practice in Texas